Portosystemic Encephalopathy without Liver Cirrhosis Masquerading as Depression

Takanori Asakura¹, Nobutake Ito², Takahiro Sohma² and Nobuaki Mori¹

Abstract

A 69-year-old woman was hospitalized due to progressive lethargy with hyperammonemia. Five months before the current admission, she was diagnosed with depression based on her low level of daily physical activity and thus began taking antidepressants. Abdominal computed tomography revealed a portosystemic shunt running between the left renal vein and inferior mesenteric vein. Balloon-occluded retrograde transvenous obliteration of the shunt vessel was performed, and the patient showed a remarkable clinical improvement. The possibility of a portosystemic shunt should be considered in the presence or absence of underlying liver disease and the ammonia level should be measured before diagnosing depression, as portosystemic encephalopathy may be reversible with interventional radiology treatment.

Key words: depression, portosystemic encephalopathy, portosystemic shunt


Introduction

Portosystemic shunts primarily occur in cases of portal hypertension with liver cirrhosis and subsequently lead to portosystemic encephalopathy, a reversible syndrome characterized by an impaired brain function. Although portosystemic encephalopathy has also been reported to develop in patients with portosystemic shunts without liver cirrhosis, many of these patients have been misdiagnosed as having dementia or other psychological disorders and the condition represents a diagnostic challenge for clinicians. We herein describe a case of portosystemic encephalopathy in a patient without liver cirrhosis who was misdiagnosed to have depression and showed a remarkable clinical improvement after undergoing balloon-occluded retrograde transvenous obliteration (B-RTO).

Case Report

A 69-year-old woman presented to our hospital with progressive lethargy. An altered mental status had been recognized six months previously. Five months before the current admission, she was diagnosed with depression by a primary care physician due to her low level of daily physical activity and began taking antidepressants. She also took glycyrrhizin (100 mg per day) for allergic dermatitis. She had no personal or family history of liver disease, such as acute or chronic viral hepatitis and autoimmune disease, abdominal injury, surgery or blood transfusions and did not drink alcohol or use illicit drugs. Her Glasgow Coma Scale was 12 (E2V4M6). Her blood pressure was 158/94 mmHg, her body temperature was 39.1°C, her pulse rate was 131 beats per minute, her respiratory rate was 16 breaths per minute and her oxygen saturation was 98% on ambient air. In addition, her weight was 56.5 kg, her height was 149.8 cm and her body mass index was 25.2 kg/m². A physical examination showed asterixis, although no other signs indicative of liver cirrhosis, such as jaundice, spider angioma, palmar erythema, an increased liver size or ascites, were noted. Furthermore, there were no signs of meningeal irritation, and the physical and neurological findings were unremarkable. The results of laboratory tests are shown in Table. The findings of a cerebral fluid analysis were normal, and abdominal ultrasonography showed only fatty liver, with no evidence of an intrahepatic shunt or splenomegaly. Meanwhile, an ab-

¹Department of General Internal Medicine, National Hospital Organization Tokyo Medical Center, Japan and ²Department of Radiology, National Hospital Organization Tokyo Medical Center, Japan
Received for publication August 1, 2014; Accepted for publication November 4, 2014
Correspondence to Dr. Takanori Asakura, takanori.asakura@gmail.com
RTO was selected because it is an effective and minimally invasive technique. There were no procedure-related complications, such as infection, contrast-induced nephropathy, hematoma formation, pulmonary embolism, edema or hemolysis, and esophagogastroduodenoscopy showed no gastroesophageal varices. The treatment resulted in a notable clinical improvement, and the serum ammonia level normalized. There were no portal hypertensive complications throughout the eight-month follow-up period, and the patient remained free from hyperammonemia and symptoms of depression without treatment with antidepressants.

**Discussion**

The present case of portosystemic encephalopathy involved a patient without liver cirrhosis who was currently receiving treatment for depression. In previous reports, the etiology of portosystemic encephalopathy without liver cirrhosis included congenital abnormalities in the intrahepatic vascular system, degeneration of the hepatic parenchyma and anastomosing vasculature after abdominal surgery, liver biopsy or trauma (1). In the current case, while the serum levels of hyaluronic acid and the type IV collagen 7s domain, a marker of hepatic fibrosis, were elevated, the levels of serum albumin, platelets and ferritin were normal and there were no signs of portal hypertension, such as splenomegaly or gastroesophageal varices. A liver biopsy was not performed to clarify the underlying liver disease because the patient did not consent to this procedure. Although she may have had a chronic liver disease, such as non-alcoholic fatty liver, her laboratory and imaging data indicated a preserved liver function, with the exception of ele-

Table. Laboratory Data on Admission.

<table>
<thead>
<tr>
<th>Hematology</th>
<th>Biochemistry</th>
<th>Serology</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC 13,800 /µL</td>
<td>TP 8.2 g/dL</td>
<td>CRP 2.4 mg/dL</td>
</tr>
<tr>
<td>Hb 15.8 g/dL</td>
<td>Alb 3.8 g/dL</td>
<td>IgG 1,786 mg/dL</td>
</tr>
<tr>
<td>Ht 45.5 %</td>
<td>Uric acid 10.7 mg/dL</td>
<td>IgA 256 mg/dL</td>
</tr>
<tr>
<td>Plt 29.4×10^4 /µL</td>
<td>BUN 16.2 mg/dL</td>
<td>IgM 345 mg/dL</td>
</tr>
<tr>
<td>Cr 1.04 mg/dL</td>
<td>Hb 15.8 g/dL</td>
<td>Hbs-Ag (-) 0.2 IU/mL</td>
</tr>
<tr>
<td>APTT 30.1 s</td>
<td>D-Bil 2.86 mg/dL</td>
<td>Anti-HBs (+) 18.3 index CLIA</td>
</tr>
<tr>
<td>PT% 74.2 %</td>
<td>LDH 354 IU/L</td>
<td>Anti-HBe (-) 5.7 index CLIA</td>
</tr>
<tr>
<td>PT 1.13</td>
<td>AST 77 IU/L</td>
<td>Anti-HBc (-)</td>
</tr>
<tr>
<td>FIB 340 mg/dL</td>
<td>ALT 40 IU/L</td>
<td>HBV-DNA undetectable</td>
</tr>
<tr>
<td>γ-GTP 67 IU/L</td>
<td>ALP 361 IU/L</td>
<td>HCV-Ab (-) &lt;1.0 log U/mL</td>
</tr>
<tr>
<td>ChE 163 U/L</td>
<td>AMA2 (+)</td>
<td></td>
</tr>
<tr>
<td>Na 150 mEq/L</td>
<td>ASMA (-)</td>
<td></td>
</tr>
<tr>
<td>K 2.3 mEq/L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cl 100 mEq/L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferritin 118 ng/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ammonia 228 µg/dL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


---

**Figure 1.** An abdominal computed tomography scan with contrast enhancement revealed a portosystemic shunt running between the left renal vein (arrow) and inferior mesenteric vein (arrowhead).

Abdominal computed tomography scan with contrast enhancement demonstrated a portosystemic shunt running between the left renal vein and inferior mesenteric vein (Fig. 1).

After admission, intravenous branched-chain amino acid and intracolonic lactulose were administered for portosystemic encephalopathy in addition to antibiotics, and fluid resuscitation was performed. The liver function abnormalities and hyperbilirubinemia improved; however, there was little improvement in the patient’s consciousness or serum ammonia level. Urine and blood cultures were negative. On day 7, B-RTO was performed to treat the shunt vessel and medically refractory portosystemic encephalopathy (Fig. 2) B-RTO was selected because it is an effective and minimally invasive technique.
vated levels of hepatic fibrosis markers. Akahoshi et al. reported a case of pathological fibrosis of the liver with portosystemic encephalopathy in a patient without cirrhosis due to the presence of a congenital extrahepatic portosystemic shunt (2). However, follow-up studies are needed to evaluate the fibrotic changes and underlying liver disease observed in such cases.

According to our literature review, 24 cases of portosystemic encephalopathy without liver cirrhosis have been reported, including 20 from East Asia (3-15) and four from the USA (16-19), since Raskin et al. reported the first case in 1964 (16). Previous studies involved mostly women (83%), with a mean age of 67.5 years (range: 37-86 years). In previous reports, the portosystemic shunts were probably congenital; however, patients may be underdiagnosed simply because most physicians are unaware of this condition. Most reported cases of portosystemic encephalopathy caused by a spontaneous portosystemic shunt have occurred in subjects in their fifties, sixties and seventies. The reasons for this observation include the possibility that aging of the brain decreases the resistance of the brain tissue to the effects of ammonia and other metabolites (16), thus inducing damage to the liver parenchyma due to long-term ischemic changes associated with aging and a gradual increase in the blood flow in the shunt (17). In the present case, the following features led to the diagnosis of a spontaneous portosystemic shunt. The patient had no history of hepatic disease, and a physical examination did not reveal any signs of hepatic dysfunction. In addition, she had no history of abdominal surgery, and images showed no evidence of changes indicating liver cirrhosis or portal hypertension. Finally, serologic assays showed prior hepatitis B virus infection, and the patient exhibited no evidence of cirrhosis.

Among the cases identified in our literature review, the average time from the onset of the first symptom to diagnosis was highly variable (range: 1 day-10 years). Many patients showed psychiatric and/or neurological symptoms, and four cases were misdiagnosed as dementia (4, 7, 10, 20). Notably, the patient in our case was misdiagnosed as having depression. Although none of the previous cases were misdiagnosed as depression, portosystemic encephalopathy caused symptoms similar to depression, such as subtle psychiatric and behavioral changes (21). Watanabe et al. (1) described characteristics suspicious of portosystemic encephalopathy in patients without liver cirrhosis: 1) high blood ammonia and bile acid levels with no or slight abnormalities in the liver function, 2) the repeated development of disturbance of psychiatric symptoms in psychiatric patients and 3) abnormally large blood vessels with no portal flow detected on abdominal imaging. These findings may provide useful clues for primary care physicians in addition to the variable symptoms of portosystemic encephalopathy. In the present case, there appeared to be two reasons for the late diagnosis. First, the patient had no history of liver disease and the findings of a physical examination were not consistent with liver cirrhosis. Second, the serum ammonia level was not routinely measured.

Although surgical intervention was previously the only treatment option for portosystemic shunts, interventional radiology techniques, such as B-RTO, now constitute a more favorable, less invasive option. Nevertheless, B-RTO is associated with two major complications: early procedure-related complications and late portal hypertensive complications. Procedure-related complications include infection, contrast-induced nephropathy, hematoma formation, pulmonary embolism due to the migration of coils or thrombi, hemolysis and pulmonary edema resulting from the use of ethanolamine oleate iopamidol (22, 23). Haptoglobin is usually administered to prevent critical hemolysis, which may cause nephropathy (24, 25), as in the present case. Portal hyper-

Figure 2. A 5-Fr balloon catheter was advanced into the portogonadal shunt through the right femoral vein. After confirming nearly complete stagnation on balloon occlusion venography (A), the shunt was filled with a sclerosant (5% ethanolamine oleate iopamidol). Although the balloon was inflated and remained in place for 20 minutes after the injection, complete hemostasis was not achieved. Therefore, the balloon was left in place overnight to enhance coil embolization of the shunt (B). A computed tomography scan obtained one week later revealed complete occlusion of the portogonadal shunt (C, the arrows indicate thrombi in the shunting vein).
tensive complications due to reperfusion of the shunt vessel flow include the de novo occurrence or aggravation of pre-existing gastroesophageal varices or portal hypertensive gastropathy, ascites or spontaneous bacterial peritonitis (22, 23, 26).

In a European multicenter cohort study, 41% of the patients with liver cirrhosis experienced recurrent hepatic encephalopathy within 100 days after embolization (26). However, in our literature review, recurrent hepatic encephalopathy was not reported in patients without liver cirrhosis, and all patients were free of hepatic encephalopathy for more than 12 months (8-10, 15, 19). Embolization of portosystemic shunts may be more effective in patients without liver cirrhosis due to their greater preservation of the liver function and reduced portal blood pressure versus those with liver cirrhosis. In the present case, a notable improvement and reduced portal blood pressure versus those with cirrhosis due to their greater preservation of the liver function.

In conclusion, the possibility of a portosystemic shunt should be considered in the presence or absence of underlying liver disease and the ammonia level should be measured before diagnosing depression, as portosystemic encephalopathy may be reversible with interventional radiology treatment.

The authors state that they have no Conflict of Interest (COI).

References


